US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Canada’s NanoVation Therapeutics, a privately-held platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, has announced a multi-year partnership with Danish drugmaker Novo Nordisk. 18 September 2024
Gene therapy research in Japan has gained significant momentum due to the SAKIGAKE designation system and government-led initiatives like the “Project for Regenerative/Cellular Medicine and Gene Therapies” to accelerate research and development (R&D) to create new technologies for gene/cell therapy. 18 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
California, USA-based biotech BridgeBio Pharma saw its shares dip 4% to $29.60 yesterday on disappointing clinical results and the company’s decision to drop an early-stage candidate. 11 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted what it regards as the UK's potential to lead the global cell and gene therapy sector. 5 September 2024
Arsenal Biosciences, a programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, has announced the close of an oversubscribed $325 million Series C financing round. 4 September 2024
Chinese gene therapy specialist YolTech Therapeutics has entered into an exclusive licensing agreement with Salubris Pharmaceuticals (SHE: 002294). 3 September 2024
The UK’s National Health Service (NHS) got off to a good start with the introduction of cell and gene therapies but it must do more to get ready for the arrival of the advanced therapies of the future, according to a new report for the Association of the British Pharmaceutical Industry (ABPI). 19 August 2024
Japanese drugmaker Chugai Pharmaceutical has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for gene therapy delandistrogene moxeparvovec, for the treatment of Duchenne muscular dystrophy (DMD). 15 August 2024
CRISPR genome-editing biopharma company Caribou Biosciences has announced the appointment of Tina Albertson as chief medical officer (CMO). 13 August 2024
Californian genetic medicines company 4D Molecular Therapeutics is free to continue with its Phase I/II INGLAXA study for the gene therapy 4D-310 in Fabry disease cardiomyopathy. 12 August 2024
Vertex Pharmaceuticalsrevealed a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel), from today. 8 August 2024
The US Food and Drug Administration (FDA) has granted accelerated approval for a new indication of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy from US pharma major Bristol Myers Squibb (NYSE: BMY). 16 March 2024
Cell and gene therapies (CGTs) have shown impressive clinical benefits for patients worldwide, with 89 approved therapies reported globally as of second-quarter 2023. 15 March 2024
Britain’s health technology assessor (HTA) is moving to recommend against funding Casgevy (exagamglogene autotemcel), the second such blow for people with sickle cell disease (SCD) in the country. 15 March 2024
Cartesian Therapeutics has revealed in a stock exchange filing that it has received notice from Japanese pharma major Astellas’ subsidiary Audentes Therapeutic that it is terminating their license and development agreement. 15 March 2024
Sweden-headquartered contract development and manufacturing organization (CDMO) Recipharm says that its ReciBioPharm unit has entered a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical US gene therapy company 13 March 2024
Early data from the AFFINITY DUCHENNE trial of a new gene therapy, RGX-202, raise hopes for a breakthrough in Duchenne muscular dystrophy (DMD). 6 March 2024
Progress is happening in the cell and gene therapies (CGT) space—but that does not mean that the challenges that have held it back are about to disappear. 6 March 2024
Beacon Therapeutics’ gene therapy AGTC-501 (laruparetigene zovaparvovec) is in the spotlight with encouraging interim results from SKYLINE trial in the retinitis pigmentosa (retinitis) market. 5 March 2024
Swiss pharma giant Novartis today presented new data that continue to support the clinical benefits of Zolgensma (onasemnogene abeparvovec), the only one-time gene therapy for the treatment of spinal muscular atrophy (SMA). 4 March 2024
There is a ray of hope for sickle cell disease (SCD) patients in the UK, after the British health technology assessor re-opened its review into Oxbryta (voxelotor). 1 March 2024
In December 2023, the US Food and Drug Administration (FDA) released a 25-page draft guidance on Potency Assurance for Cellular and Genetic Therapy Products.1 1 March 2024
British pharma major AstraZeneca has chosen Shanghai as the location for what will become its fifth global strategic center for research and development. 29 February 2024
San Diego, USA-based Kenai Therapeutics, a biotech leveraging induced pluripotent stem cell (iPSC) tech to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, has raised $82 million in a Series A financing. 29 February 2024
US clinical-stage cell therapy developer Vittoria Biotherapeutics today said that accomplished life sciences leader, Rosemary Mazanet, has joined the company as chief medical officer. 27 February 2024
Japan’s largest drugmaker Takeda decided to discontinue the development programs of its four oncology assets - Phase III asset modakafusp alfa (TAK-573) and three Phase I chimeric antigen receptor (CAR-T) assets: TAK-102, TAK-103 and TAK-940 - as part of a plan to align its focus on advancing allogeneic cell therapies. 23 February 2024
PolTREG, a Polish biotech developing cell therapies for autoimmune diseases, has named Daniel Shelly its chief business development officer. 21 February 2024
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Amtagvi (lifileucel) suspension for intravenous infusion, submitted by US biotech Iovance Biotherapeutics. 19 February 2024